Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 69 Published: March 31, 2022 Report Code: GMDGDHC22078IDB

Cluster headache is pain that occurs along one side of the head. It frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing, and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

The Cluster Headache Syndrome (Cluster Headache) Drugs in Development market research report provides an overview of the Cluster Headache Syndrome (Cluster Headache) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Cluster Headache), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects.

Cluster Headache Pipeline Drugs Market Targets

The targets of the cluster headache pipeline drugs market are 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 1D, Calcitonin Gene Related Peptide, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide Type 1 Receptor, 5-Hydroxytryptamine Receptor 2C, Calcium Channel, Cannabinoid Receptor 1, and Cannabinoid Receptor 2.

Cluster headache pipeline drugs market, by targets

Cluster headache pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of Cluster Headache Pipeline Drugs Market

The mechanisms of action of the cluster headache pipeline drugs market are 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 1D Agonist, Calcitonin Gene Related Peptide Inhibitor, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Agonist, Calcium Channel Blocker, and Cannabinoid Receptor 1 Agonist.

Cluster headache pipeline drugs market, by mechanisms of action

Cluster headache pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Cluster Headache Pipeline Drugs Market

The routes of administration in the cluster headache pipeline drugs market are oral, subcutaneous, nasal, intramuscular, intravenous, intraarticular, intradermal, parenteral, topical, and transdermal.

Cluster headache pipeline drugs market, by routes of administration

Cluster headache pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Cluster Headache Pipeline Drugs Market

The molecule types in the cluster headache pipeline drugs market are small molecule and monoclonal antibody.

Cluster headache pipeline drugs market, by molecule types

Cluster headache pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key Cluster Headache Pipeline Drugs Market Companies

Some of the key companies in the cluster headache pipeline drugs market are Ceruvia Lifesciences LLC, Eli Lilly and Co, Amgen Inc, Amneal Pharmaceuticals Inc, Better Life Pharmaceuticals Inc, Biohaven Pharmaceutical Holding Company Ltd, Bright Minds Biosciences Inc, CCH Pharmaceuticals ApS, Clexio Biosciences Ltd, and Crossject SA.

Cluster headache pipeline drugs market, by key companies

Cluster headache pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 1D, Calcitonin Gene Related Peptide, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide Type 1 Receptor, 5-Hydroxytryptamine Receptor 2C, Calcium Channel, Cannabinoid Receptor 1, and Cannabinoid Receptor 2
Mechanisms of Action 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 1D Agonist, Calcitonin Gene Related Peptide Inhibitor, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Agonist, Calcium Channel Blocker, and Cannabinoid Receptor 1 Agonist
Routes of Administration Oral, Subcutaneous, Nasal, Intramuscular, Intravenous, Intraarticular, Intradermal, Parenteral, Topical, and Transdermal
Molecule Types Small Molecule and Monoclonal Antibody
Key Companies Ceruvia Lifesciences LLC, Eli Lilly and Co, Amgen Inc, Amneal Pharmaceuticals Inc, Better Life Pharmaceuticals Inc, Biohaven Pharmaceutical Holding Company Ltd, Bright Minds Biosciences Inc, CCH Pharmaceuticals ApS, Clexio Biosciences Ltd, and Crossject SA

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
  • Reviews of pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Evaluation of Cluster Headache Syndrome (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Amgen Inc

Amneal Pharmaceuticals Inc

Better Life Pharmaceuticals Inc

Biohaven Pharmaceutical Holding Company Ltd

Bright Minds Biosciences Inc

CCH Pharmaceuticals ApS

Ceruvia Lifesciences LLC

Clexio Biosciences Ltd

Crossject SA

Eli Lilly and Co

H. Lundbeck AS

Havn Life Sciences Inc

Mind Medicine MindMed Inc

NeuroPharm Inc

Psirenity Inc

Shackelford Pharma Inc

Winston Pharmaceuticals Inc

Xgene Pharmaceutical Inc

Zosano Pharma Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cluster Headache Syndrome (Cluster Headache) – Overview

Cluster Headache Syndrome (Cluster Headache) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cluster Headache Syndrome (Cluster Headache) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cluster Headache Syndrome (Cluster Headache) – Companies Involved in Therapeutics Development

Amgen Inc

Amneal Pharmaceuticals Inc

Better Life Pharmaceuticals Inc

Biohaven Pharmaceutical Holding Company Ltd

Bright Minds Biosciences Inc

CCH Pharmaceuticals ApS

Ceruvia Lifesciences LLC

Clexio Biosciences Ltd

Crossject SA

Eli Lilly and Co

H. Lundbeck AS

Havn Life Sciences Inc

Mind Medicine MindMed Inc

NeuroPharm Inc

Psirenity Inc

Shackelford Pharma Inc

Winston Pharmaceuticals Inc

Xgene Pharmaceutical Inc

Zosano Pharma Corp

Cluster Headache Syndrome (Cluster Headache) – Drug Profiles

BETR-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CLE-500 – Drug Profile

Product Description

Mechanism Of Action

dihydroergotamine mesylate (DHE) – Drug Profile

Product Description

Mechanism Of Action

eptinezumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

erenumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

galcanezumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

ketamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

lysergic acid diethylamide – Drug Profile

Product Description

Mechanism Of Action

History of Events

NYPRG-101 – Drug Profile

Product Description

Mechanism Of Action

psilocybin – Drug Profile

Product Description

Mechanism Of Action

psilocybin – Drug Profile

Product Description

Mechanism Of Action

psilocybin – Drug Profile

Product Description

Mechanism Of Action

rimegepant sulfate ODT – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Cluster Headache Syndrome (Cluster Headache) – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Agonize 5-HT2A and 5-HT2C for Pain – Drug Profile

Product Description

Mechanism Of Action

SPID-001 – Drug Profile

Product Description

Mechanism Of Action

sumatriptan – Drug Profile

Product Description

Mechanism Of Action

XG-043 – Drug Profile

Product Description

Mechanism Of Action

zolmitriptan – Drug Profile

Product Description

Mechanism Of Action

History of Events

zucapsaicin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cluster Headache Syndrome (Cluster Headache) – Dormant Projects

Cluster Headache Syndrome (Cluster Headache) – Discontinued Products

Cluster Headache Syndrome (Cluster Headache) – Product Development Milestones

Featured News & Press Releases

Nov 16, 2021: BetterLife Obtains TD-0148A behavioural pharmacology data confirming its projected non-hallucinogenic property

Sep 29, 2021: BetterLife obtains TD-0148A receptor binding data for IND-enabling pharmacology studies

Sep 27, 2021: BetterLife files patent for TD-0148A for treatment of cluster headaches and related disorders

Jun 07, 2021: Amneal announces Dihydroergotamine (DHE) autoinjector NDA for migraines and cluster headaches

Feb 25, 2021: Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

Jun 08, 2020: Phase 2 clinical trial of LSD for “Suicide Headaches” begins treating patients

Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality

Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache

Jun 05, 2019: FDA approves first drug for episodic cluster headaches

May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio

Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults

Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache

May 15, 2018: Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Amgen Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Amneal Pharmaceuticals Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Better Life Pharmaceuticals Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Bright Minds Biosciences Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by CCH Pharmaceuticals ApS, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Ceruvia Lifesciences LLC, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Clexio Biosciences Ltd, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Crossject SA, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Eli Lilly and Co, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by H. Lundbeck AS, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Havn Life Sciences Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Mind Medicine MindMed Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by NeuroPharm Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Psirenity Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Shackelford Pharma Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Winston Pharmaceuticals Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Xgene Pharmaceutical Inc, 2022

Cluster Headache Syndrome (Cluster Headache) – Pipeline by Zosano Pharma Corp, 2022

Cluster Headache Syndrome (Cluster Headache) – Dormant Projects, 2022

Cluster Headache Syndrome (Cluster Headache) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.